Why measuring in solution matters: antibody interactions with amyloid species

This webinar was presented by Sebastian Fiedler, Lead Application Scientist at Fluidic Analytics.

In the webinar Sebastian covered how the Fluidity One-M was used by Lund University, Sweden to “obtain unique information that could not have been obtained with other technologies*” including how our technology Determines affinity of interaction (KD), size, and stoichiometry of the complex, all in a single experiment; Provides painless characterisation of disordered proteins or higher-order complexes under immobilisation-free conditions; Reveals a clear picture of the overall mechanism of action between different species by understanding binding.

Immune responses to SARS-CoV-2

Understanding the nature of the immune response that leads to recovery from severe disease is key to developing effective treatments for COVID-19. In this webinar, Professor Akiko Iwasaki will discuss immune responses in COVID-19 patients with moderate and severe disease. She will compare viral load, immune phenotype and cytokines that are predictive of mortality, and discuss signatures of cytokines and growth factors that associate with recovery vs. disease exacerbation.

New insights into the mechanisms of action of anti-Abeta antibodies

In this webinar, Prof. Linse discusses new methods that have yielded new insights into the mechanisms of action of four clinical-stage anti-Abeta antibodies: aducanumab, gatenerumab, bapineuzumab and solanezumab. Kinetic analyses were combined with binding measurements performed using microfluidic diffusional sizing (MDS) to quantify the influence of these antibodies on the aggregation kinetics and on the production of oligomeric aggregates. It was demonstrated that these effects were linked to the affinity and stoichiometry of each antibody for monomeric and fibrillar forms of Abeta. These results reveal that, uniquely among these four antibodies, aducanumab dramatically reduces the flux of Abeta oligomers.

Population-wide immune responses to SARS‑CoV‑2:
Insights from quantifying the antibody response

Prof. Adriano Aguzzi outlines the challenge in understanding the humoral immune response to COVID‑19, and therefore, predicting the degree of immune protection resulting from previous infection, vaccination and other treatments.

Measuring What Really Matters: Safe, Rapid & Variant-Specific Affinity-Based Virus-Neutralization Assays

We present a new type of rapid assay that is based on quantifying these protein interactions and provides functional insights.

All antibodies are NOT created equal: Comprehensive profiling of SARS-CoV-2 antibodies

Detecting antibodies that confer effective immunity is crucially important in the fight against SARS-CoV-2.

Accurate solution phase affinity profiling of a SARS-CoV-2 antibody in serum

Measuring antibody affinity in serum – it’s not as trivial as it sounds

Affinity vs Avidity — What’s the difference?

We explore the differences between Affinity vs Avidity and hopefully dispel the vagueness you feel next time you come across them in a paper

Monitoring of SMALP nanodisc formation by microfluidic diffusional sizing

MDS is an ideal tool to monitor SMALP nanodisc formation discover why in this webinar

Affinity of PD-1/PD-L1 interaction — a comparison between SPR, MST, ITC and MDS

Determination of binding affinity and stoichiometry of protein interactions without prior knowledge of the structure

This webinar details new methods that have yielded new insights into the mechanisms of action of four clinical-stage anti-Abeta antibodies: aducanumab, gatenerumab, bapineuzumab and solanezumab. Kinetic analyses were combined with binding measurements performed using microfluidic diffusional sizing (MDS) to quantify the influence of these antibodies on the aggregation kinetics and on the production of oligomeric aggregates. It was demonstrated that these effects were linked to the affinity and stoichiometry of each antibody for monomeric and fibrillar forms of Abeta. These results reveal that, uniquely among these four antibodies, aducanumab dramatically reduces the flux of Abeta oligomers.

In this webinar, Prof. Linse discusses:

• The mechanisms of growth of amyloid species in Alzheimer’s disease
• The different mechanisms of action of four clinical-stage antibody therapeutics
• The roles that affinity, stoichiometry, aggregation state and kinetics can play in differentiating the mechanisms of action of drugs that bind the same target